Company Expects to Apply to List Its U.S. ADRs on the NYSE MKT
Continue ReadingTag: israeli-biotech
Can-Fite BioPharma-s CF101 Drug Selected as one of the “Top Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Elsevier Business Intelligence
CF101 Is Currently in Phase III Trials for Psoriasis and Phase II for Rheumatoid Arthritis
Continue ReadingCan-Fite BioPharma to Present Its Liver Cancer Drug at the 18th World Congress on Advances in Oncology in Greece
Phase II Trial to Commence Under FDA Orphan Drug Designation
Continue ReadingCan-Fite-s Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum
To Showcase Clinical Data on CF101 for Treatment of Glaucoma
Continue ReadingCan-Fite CEO Pnina Fishman Interviewed on CorporateProfile.com
PETACH TIKVA, ISRAEL -- (Marketwired) -- 09/23/13 -- (TASE: CFBI), (PINKSHEETS: CANFY), a biotechnology company with…
Continue ReadingCan-Fite-s Level II ADRs Commence Trading on the U.S. OTC Markets
PETACH TIKVA, ISRAEL -- (Marketwired) -- 09/12/13 -- (TASE: CFBI), (OTCQB: CANFY), a biotechnology company with…
Continue Reading